• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高剂量甲泼尼龙磷酸酯和半琥珀酸酯的比较药代动力学

Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses.

作者信息

Möllmann H, Rohdewald P, Barth J, Möllmann C, Verho M, Derendorf H

机构信息

Medicinal Clinic, University of Bochum, West Germany.

出版信息

Pharm Res. 1988 Aug;5(8):509-13. doi: 10.1023/a:1015921408870.

DOI:10.1023/a:1015921408870
PMID:3072558
Abstract

The pharmacokinetics of methylprednisolone and two methylprednisolone esters, the phosphate and the hemisuccinate, were investigated after intravenous administration of the esters to 12 healthy male subjects in two different doses (250 and 1000 mg). Methylprednisolone was formed more rapidly from phosphate than from hemisuccinate. During the first 30 min methylprednisolone levels were three to four times higher after phosphate administration than after hemisuccinate. The mean residence time of the hemisuccinate was significantly longer and the total-body clearance lower than those of the phosphate. Whereas very little of the phosphate (mean, 1.7%) was eliminated unchanged into the urine, there were significant amounts of hemisuccinate (mean, 14.7%) excreted renally and therefore not bioavailable. Methylprednisolone saliva levels paralleled plasma levels; the average saliva/plasma ratio was 0.22. Neither phosphate nor hemisuccinate could be detected in saliva. An average of 7.2% of the administered dose was eliminated in the form of methylprednisolone in urine. Renal clearance was 24 ml/min and not dose or prodrug dependent. For both doses endogenous hydrocortisone levels were lowered after 24 hr. For the 1000-mg dose the depression was still significant after 48 hr. The results indicate that methylprednisolone phosphate results in a faster and more efficient conversion to its active form, methylprednisolone, than methylprednisolone hemisuccinate.

摘要

对12名健康男性受试者静脉注射两种不同剂量(250毫克和1000毫克)的甲泼尼龙酯(磷酸酯和半琥珀酸酯)后,研究了甲泼尼龙以及这两种甲泼尼龙酯的药代动力学。甲泼尼龙从磷酸酯形成的速度比从半琥珀酸酯更快。在最初30分钟内,注射磷酸酯后甲泼尼龙的水平比注射半琥珀酸酯后高三到四倍。半琥珀酸酯的平均驻留时间明显更长,全身清除率低于磷酸酯。磷酸酯极少(平均1.7%)以原形经尿液排出,而有大量半琥珀酸酯(平均14.7%)经肾脏排泄,因此无生物利用度。甲泼尼龙的唾液水平与血浆水平平行;唾液/血浆平均比值为0.22。在唾液中未检测到磷酸酯和半琥珀酸酯。平均7.2%的给药剂量以甲泼尼龙形式经尿液排出。肾脏清除率为24毫升/分钟,与剂量或前体药物无关。两种剂量给药后24小时内内源性氢化可的松水平均降低。对于1000毫克剂量,48小时后这种降低仍很显著。结果表明,与甲泼尼龙半琥珀酸酯相比,甲泼尼龙磷酸酯能更快、更有效地转化为其活性形式甲泼尼龙。

相似文献

1
Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses.高剂量甲泼尼龙磷酸酯和半琥珀酸酯的比较药代动力学
Pharm Res. 1988 Aug;5(8):509-13. doi: 10.1023/a:1015921408870.
2
Pharmacokinetics and dose linearity testing of methylprednisolone phosphate.磷酸甲泼尼龙的药代动力学及剂量线性测试
Biopharm Drug Dispos. 1989 Sep-Oct;10(5):453-64. doi: 10.1002/bdd.2510100504.
3
Kinetics of methylprednisolone and its hemisuccinate ester.甲泼尼龙及其半琥珀酸酯的动力学
Clin Pharmacol Ther. 1985 May;37(5):502-7. doi: 10.1038/clpt.1985.79.
4
Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease.琥珀酸甲泼尼龙和甲泼尼龙在慢性肝病中的药代动力学
J Clin Pharmacol. 1993 Sep;33(9):805-10. doi: 10.1002/j.1552-4604.1993.tb01955.x.
5
Simultaneous analysis of methylprednisolone hemisuccinate, cortisol and methylprednisolone by normal-phase high-performance liquid chromatography in human plasma.采用正相高效液相色谱法同时分析人血浆中半琥珀酸甲泼尼龙、皮质醇和甲泼尼龙。
J Chromatogr. 1988 Nov 18;432:308-14. doi: 10.1016/s0378-4347(00)80658-1.
6
Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers.对健康志愿者单次及多次静脉注射甲泼尼龙琥珀酸钠和甲泼尼龙舒来坦后甲泼尼龙药代动力学的初步研究。
J Clin Pharmacol. 1994 Nov;34(11):1109-15. doi: 10.1002/j.1552-4604.1994.tb01988.x.
7
Pharmacokinetics of methylprednisolone sodium succinate and methylprednisolone in patients undergoing cardiopulmonary bypass.接受体外循环的患者中琥珀酸甲泼尼龙和甲泼尼龙的药代动力学
Pharmacotherapy. 1990;10(1):29-34.
8
Rapid method for the measurement of methylprednisolone and its hemisuccinate in plasma and urine following "pulse therapy" by high-performance liquid chromatography.高效液相色谱法快速测定“冲击疗法”后血浆和尿液中甲基泼尼松龙及其半琥珀酸盐的含量
J Chromatogr. 1985 Aug 9;342(2):251-60. doi: 10.1016/s0378-4347(00)84515-6.
9
Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.酮康唑对甲泼尼龙处置的影响及其对内源性皮质醇的联合抑制作用。
Clin Pharmacol Ther. 1987 Oct;42(4):465-70. doi: 10.1038/clpt.1987.179.
10
Population pharmacokinetics of methylprednisolone in accident victims with spinal cord injury.脊髓损伤事故受害者中甲基强的松龙的群体药代动力学。
Int J Clin Pharmacol Ther. 2004 Sep;42(9):504-11. doi: 10.5414/cpp42504.

引用本文的文献

1
Meta-Analysis of the Input and Disposition of Various Dosage Forms of Methylprednisolone in Healthy Subjects Utilizing a Physiologically Based Pharmacokinetic Model.基于生理药代动力学模型对健康受试者中不同剂型甲泼尼龙的输入与处置的Meta分析。
AAPS J. 2025 Jan 9;27(1):24. doi: 10.1208/s12248-024-01011-8.
2
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.治疗炎症性肠病的临床药代动力学和药效学考虑因素。
Clin Pharmacokinet. 2018 Sep;57(9):1075-1106. doi: 10.1007/s40262-018-0639-4.
3
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

本文引用的文献

1
Simultaneous determination of glucocorticoid alcohols, their succinates and hydrocortisone in plasma.
J Pharm Biomed Anal. 1985;3(6):566-73. doi: 10.1016/0731-7085(85)80074-1.
2
HPLC determination of glucocorticoid alcohols, their phosphates and hydrocortisone in aqueous solutions and biological fluids.高效液相色谱法测定水溶液和生物流体中的糖皮质醇、其磷酸盐及氢化可的松。
J Pharm Biomed Anal. 1986;4(2):197-206. doi: 10.1016/0731-7085(86)80042-5.
3
Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration.类风湿关节炎患者“大剂量”脉冲给药后甲泼尼龙的全身生物利用度和药代动力学
综述文章:用于治疗炎症性肠病的药物的药代动力学和药效学
Eur J Clin Pharmacol. 2015 Jul;71(7):773-99. doi: 10.1007/s00228-015-1862-7. Epub 2015 May 27.
4
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.全身给药糖皮质激素的药代动力学和药效学。
Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003.
5
Pharmacokinetic considerations in the treatment of inflammatory bowel disease.炎症性肠病治疗中的药代动力学考量
Clin Pharmacokinet. 2001;40(10):723-51. doi: 10.2165/00003088-200140100-00003.
6
[Clinical experiences and results of high-dosage methylprednisolone therapy in spinal cord trauma 1991 to 1993].[1991年至1993年脊髓损伤大剂量甲基强的松龙治疗的临床经验与结果]
Unfallchirurgie. 1995 Feb;21(1):20-9. doi: 10.1007/BF02588347.
7
High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response.类风湿关节炎患者高剂量口服甲泼尼龙:药代动力学与临床反应
Eur J Clin Pharmacol. 1992;42(1):85-8. doi: 10.1007/BF00314925.
8
The in vitro enzymic labilities of chemically distinct phosphomonoester prodrugs.化学性质不同的磷酸单酯前药的体外酶促不稳定性。
Pharm Res. 1992 Apr;9(4):497-503. doi: 10.1023/a:1015840329786.
Biopharm Drug Dispos. 1983 Jul-Sep;4(3):233-48. doi: 10.1002/bdd.2510040305.
4
Kinetics of methylprednisolone and its hemisuccinate ester.甲泼尼龙及其半琥珀酸酯的动力学
Clin Pharmacol Ther. 1985 May;37(5):502-7. doi: 10.1038/clpt.1985.79.
5
Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults.成人中甲基泼尼松龙与泼尼松龙的药代动力学与剂量的关系
Eur J Clin Pharmacol. 1986;30(3):323-9. doi: 10.1007/BF00541537.
6
The clinical pharmacology of methylprednisolone sodium phosphate. I. Intramuscular route of administration.磷酸甲泼尼龙的临床药理学。I. 肌肉注射给药途径。
J Clin Pharmacol. 1977 May-Jun;17(5-6):324-33. doi: 10.1002/j.1552-4604.1977.tb04612.x.